We summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...
Read moreThe short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...
Read moreWe investigate Single Technology Appraisals (STAs) conducted by NICE, comparing outcomes for monothe...
Read moreThe MHRA awards Innovation Passports to those products it deems innovative, in order for them to be ...
Read moreThe Haute Autorité de Santé (HAS), recently announced changes to the conditions in which a drug wi...
Read moreOur Market Access analysts summarise the EUnetHTA draft scoping process and provide considerations a...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreAZ has warned its China revenues will decline mid-single-digit percentage in 2022 after years of dou...
Read moreThe HTA initially recommended Tremfya as a treatment option for adults with active psoriatic arthrit...
Read moreThe EUNetHTA recently published its draft scoping guidance which outlines how the contrasting decisi...
Read more